2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Neoplasms
7
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Lung Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Pain
2
Motor Activity
2
Hematopoietic and Lymphatic System Neoplasm
2
Carcinoma, Non-Small-Cell Lung
2
Breast Carcinoma In Situ
2
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Sedentary Behavior
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Pulmonary Disease, Chronic Obstructive
1
Polyps
1
Patient Satisfaction
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Neuromuscular Junction Diseases
1
Nervous System Diseases
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Myasthenia Gravis
1
Muscle Weakness
1
Metastatic Pancreatic Adenocarcinoma
1
Malignant Hepatobiliary Neoplasm
1
Interventions
Cyclophosphamide
14
fludarabine
9
fludarabine phosphate
8
Busulfan
5
Bendamustine Hydrochloride
5
Tacrolimus
4
Rituximab
4
Mycophenolic Acid
4
ibrutinib
3
Melphalan
3
Bortezomib
3
AP 1903 reagent
3
tetulomab tetraxetan lu-177
2
ponatinib
2
pembrolizumab
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Lutetium
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
Bone Marrow Transplantation
2
thymoglobulin
1
pimonidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immune System Diseases
×
Telemedicine
×
Clear all
NCT05917184
2023-06-23
ADAPT-teleMG
Yale University
Completed
52 enrolled